June 9, 2021 - The first analysis of medical evidence on domestic mass shooters in the U.S. finds that a large majority of perpetrators have psychiatric disorders for which they have received no medication or other treatment, reports a study in the Journal of Clinical Psychopharmacology. The journal is published in the Lippincott portfolio by Wolters Kluwer.
"Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers, and the public should be made aware that some unmedicated patients do pose an increased risk of violence," according to the report by Ira D. Glick, MD, of Stanford University School of Medicine and colleagues.
In-depth analysis of psychiatric evidence on domestic mass shooters
The researchers identified 115 persons identified as committing a mass shooting in the United States from 1982 to 2019, based on the most comprehensive listing available (the Mother Jones database). The database excluded shootings related to "conventionally motivated" crimes such as armed robbery or gang violence.
"In the vast majority of the incidents identified in the database, the perpetrator died either during or shortly after the crime," the researchers note. They focused on the 35 cases where the assailant survived and underwent criminal proceedings - providing the best information on their symptoms of mental illness and psychiatric state.
For each mass shooting event, the researchers spent hours analyzing records or interviewing the forensic psychiatrists or psychologists who examined the assailant after the crime. Other sources of information included court proceedings, public records, videotaped interviews, and social media posts or writings by the perpetrator. Dr. Glick's coauthors were Nina E. Cerfolio, MD, of the Icahn School of Medical at Mount Sinai Hospital, New York; Danielle Kamis, MD, of Stanford; and Michael Laurence, JD, a prominent capital defense attorney.
"Based on this data, 32 of the 35 perpetrators had signs and symptoms of brain illness, which fit scientific diagnostic criteria for a clinical psychiatric disorder," Dr. Glick comments. Eighteen of the shooters had schizophrenia while 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders, and substance-related disorders. In three cases, there was not enough information to make a diagnosis; in four cases, no psychiatric diagnosis was found.
Of the 28 surviving assailants with a psychiatric diagnosis, "None were medicated or received other treatment prior to the crime," the researchers write. They also analyzed 20 mass shooters who died at the crime scene, using available data from the media or significant others. Eight assailants had schizophrenia, seven had other diagnoses, five had unknown diagnoses. Similarly, none were receiving appropriate medications.
Despite the tragically high frequency of mass shooting events, there has been almost no medical research on the nature and incidence of brain illness among the perpetrators of these crimes. The study originated in Dr. Glick's clinical impression that many, if not most, mass shooters are people with unidentified psychiatric illness - complicated by a lack of support from family or significant others in getting the help they needed.
The authors acknowledge some important limitations of their study: it included only limited evidence on a small group of domestic shooters who survived, with no comparison group. "Nonetheless," the researchers write, "our data suggest that persons who commit mass murders may suffer from compromising and untreated psychiatric illness."
"The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses - as much in need of proper diagnosis and treatment as heart disease or any other medical condition," Dr. Glick adds. "We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments. By actually talking to patients and their significant others, we have the opportunity to save lives."
About the Journal of Clinical Psychopharmacology
Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
Journal of Clinical Psychopharmacology